A Randomized Study Comparing Parathyroidectomy with @entity4046 for Treating @entity2741 in Kidney Allograft Recipients with XXXX .

@entity1 @entity3747 @entity2741 @entity470 @entity4613 @entity729 @entity4046 @entity512 @entity2742
UNASSIGNED: @entity2742 is a common cause of @entity2741 after kidney transplant. We designed this 12-month, prospective, multicenter, open-label, randomized study to evaluate whether @entity512 is more effective than @entity4046 for controlling @entity2741 caused by persistent @entity2742 after kidney transplant. Kidney allograft recipients with @entity2741 and elevated intact parathyroid hormone (iPTH) concentration were eligible if they had received a transplant >= 6 months before the study and had an @entity470 >30 ml/min per 1.73 m(2). The primary end point was the proportion of @entity1 with normocalcemia at 12 months. Secondary end points were serum iPTH concentration, serum @entity4613 concentration, bone mineral density, @entity729 , renal function, @entity1 and graft survival, and economic cost. In total, 30 @entity1 were randomized to receive @entity4046 (n=15) or @entity512 (n=15). At 12 months, ten of 15 @entity1 in the @entity4046 group and 15 of 15 @entity1 in the parathyroidectomy group (P=0.04) achieved normocalcemia. Normalization of serum @entity4613 concentration occurred in almost all @entity1 . @entity512 induced greater reduction of iPTH and associated with a significant increase in femoral neck bone mineral density; @entity729 remained unchanged in both groups. The most frequent adverse events were digestive intolerance in the @entity4046 group and @entity3747 in the parathyroidectomy group. Surgery would be more cost effective than @entity4046 if @entity4046 duration reached 14 months. All @entity1 were alive with a functioning graft at the end of follow-up. In conclusion, @entity512 was superior to @entity4046 in controlling @entity2741 in these @entity1 with kidney transplants and persistent @entity2742 .
